利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

85 records (took 0.025 seconds)

    DIHYDROPYRROLO[3,4-C]PYRAZOLE DERIVATIVES AND THEIR USE IN DIAGNOSIS
    1.
    发明申请
    DIHYDROPYRROLO[3,4-C]PYRAZOLE DERIVATIVES AND THEIR USE IN DIAGNOSIS 有权

    公开(公告)号：US20250042905A1

    公开(公告)日：2025-02-06

    申请号：US18708694

    申请日：2022-11-10

    Applicant: AC IMMUNE SA

    Inventor： Jérôme Molette

    IPC: C07D487/04 ,  A61K51/04

    Abstract: The present invention relates to novel compounds of formula (I), or a detectably labelled compound, stereoisomer, racemic mixture, pharmaceutically acceptable salt, hydrate, or solvate thereof, that can be employed in the imaging of alpha-synuclein aggregates and determining an amount thereof. Furthermore, the compounds can be used for diagnosing a disease, disorder or abnormality associated with an alpha-synuclein aggregates, including, but not limited to, Lewy bodies, Lewy neurites and/or cytoplasmic glial inclusions (such as Parkinson's disease), determining a predisposition to such a disease, disorder or abnormality, prognosing such a disease, disorder or abnormality, monitoring the evolution of the disease in a patient suffering from such a disease, disorder or abnormality, monitoring the progression of such a disease, disorder or abnormality and predicting responsiveness of a patient suffering from such a disease, disorder or abnormality to a treatment thereof.

    BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY
    4.
    发明公开
    BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY 审中-公开

    公开(公告)号：US20240051967A1

    公开(公告)日：2024-02-15

    申请号：US18114654

    申请日：2023-02-27

    Applicant: AC IMMUNE SA

    Inventor： Jérôme MOLETTE ,  Emanuele GABELLIERI ,  Vincent DARMENCY

    IPC: C07D495/04 ,  C07D417/14 ,  C07D513/04 ,  A61K51/04 ,  C07B59/00

    CPC classification number: C07D495/04 ,  C07D417/14 ,  C07B2200/05 ,  A61K51/0431 ,  C07B59/002 ,  C07D513/04

    Abstract: The present invention relates to novel compounds that can be employed in the diagnosis, monitoring of disease progression or monitoring of drug activity, of a group of disorders and abnormalities associated with alpha-synuclein (α-synuclein, A-synuclein, aSynuclein, A-syn, α-syn, aSyn) aggregates including, but not limited to, Lewy bodies and/or Lewy neurites, such as Parkinson's disease. The instant compounds are particularly useful in determining a predisposition to such a disorder, monitoring residual disorder, or predicting the responsiveness of a patient who is suffering from such a disorder to the treatment with a certain medicament. The present compounds can also be used to treat, alleviate or prevent a disorder or abnormality associated with alpha-synuclein aggregates.

    Misfolded TDP-43 Binding Molecules
    5.
    发明公开
    Misfolded TDP-43 Binding Molecules 审中-公开

    公开(公告)号：US20230340090A1

    公开(公告)日：2023-10-26

    申请号：US18045074

    申请日：2022-10-07

    Applicant: AC Immune SA

    Inventor： Tamara Seredenina ,  Oskar Adolfsson

    IPC: C07K16/18 ,  A61K47/68 ,  A61K45/06 ,  G01N33/68

    CPC classification number: C07K16/18 ,  A61K47/6843 ,  A61K47/6803 ,  A61K45/06 ,  G01N33/6896 ,  C07K2317/34 ,  C07K2317/92 ,  G01N2800/28

    Abstract: The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43). The invention relates to TDP-43 specific binding molecules, in particular to anti-TDP-43 antibodies or an antigen-binding fragment or a derivative thereof and uses thereof. The present invention provides means and methods to diagnose, prevent, alleviate and/or treat a disorder and/or abnormality associated with misfolded TDP-43 including but not limited to frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD, sporadic and familial), and/or Parkinson's disease (PD). The present invention provides modified conformation-specific antigenic peptides and peptide fragments derived from the TDP-43 protein and the antibodies obtainable by said peptides or fragments for use in the diagnosis, prevention, alleviation and/or treatment of TDP-43-related disorders and/or abnormalities.

    NOVEL COMPOUNDS FOR DIAGNOSIS
    8.
    发明公开
    NOVEL COMPOUNDS FOR DIAGNOSIS 审中-公开

    公开(公告)号：US20230174536A1

    公开(公告)日：2023-06-08

    申请号：US17923771

    申请日：2021-05-07

    Applicant: AC IMMUNE SA

    Inventor： Jerome MOLETTE

    IPC: C07D487/04 ,  C07B59/00 ,  A61K51/04

    CPC classification number: C07D487/04 ,  C07B59/002 ,  A61K51/0459 ,  A61K51/0455 ,  A61K51/0463 ,  C07B2200/05

    Abstract: The present invention relates to novel compounds of formula (I), or a detectably labelled compound, stereoisomer, racemic mixture, pharmaceutically acceptable salt, hydrate, or solvate thereof, that can be employed in the imaging of alpha-synuclein aggregates and determining an amount thereof. Furthermore, the compounds can be used for diagnosing a disease, disorder or abnormality associated with an alpha-synuclein aggregates, including, but not limited to, Lewy bodies and/or Lewy neurites (such as Parkinson's disease), determining a predisposition to such a disease, disorder or abnormality, prognosing such a disease, disorder or abnormality, monitoring the evolution of the disease in a patient suffering from such a disease, disorder or abnormality, monitoring the progression of such a disease, disorder or abnormality and predicting responsiveness of a patient suffering from such a disease, disorder or abnormality to a treatment thereof.

Patent Agency Ranking